BEAM
Beam Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$29.66
+0.68%Margins
Gross margin
18.9%
EBITDA margin
-38.6%
EBIT margin
-242.3%
Net margin
-54.7%
FCF margin
-238.9%
-8.0%
Return on equity
-6.2%
Return on assets
-28.8%
Return on invested capital
0.11x
Asset turnover
-$359.4M
Cash from operations
$11
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026